Telix Pharmaceuticals Limited (TLX)
NASDAQ: TLX · Real-Time Price · USD
11.25
-0.70 (-5.86%)
Sep 23, 2026, 12:24 PM EDT - Market open
Telix Pharmaceuticals Revenue
Telix Pharmaceuticals had revenue of $477.35M in the half year ending June 30, 2026, with 99.22% growth. This brings the company's revenue in the last twelve months to $890.79M, up 167.52% year-over-year. In the year 2025, Telix Pharmaceuticals had annual revenue of $803.79M with 55.61% growth.
Revenue (ttm)
$890.79M
Revenue Growth
+167.52%
P/S Ratio
4.32
Revenue / Employee
$752,352
Employees
1,184
Market Cap
3.85B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 803.79M | 287.24M | 55.61% |
| Dec 31, 2024 | 516.55M | 183.57M | 55.13% |
| Dec 31, 2023 | 332.98M | 224.03M | 205.64% |
| Dec 31, 2022 | 108.95M | 103.42M | 1,873.24% |
| Dec 31, 2021 | 5.52M | 1.51M | 37.53% |
| Dec 31, 2020 | 4.01M | 1.57M | 64.21% |
| Dec 31, 2019 | 2.44M | 2.31M | 1,680.88% |
| Dec 31, 2018 | 137.28K | - | - |
| Dec 31, 2017 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| ACADIA Pharmaceuticals | 1.14B |
| Iovance Biotherapeutics | 324.97M |
| IDEAYA Biosciences | 234.13M |
| AbCellera Biologics | 66.17M |
| Tango Therapeutics | 53.81M |
| Relay Therapeutics | 10.35M |
| Xenon Pharmaceuticals | 7.50M |
TLX News
- 1 day ago - Telix Pharmaceuticals Transcript: R&D Day 2026 - Transcripts
- 1 day ago - Telix Pharmaceuticals Slides: FY 2026 - Filings
- 1 day ago - Telix upgraded to Outperform from Sector Perform at RBC Capital - TheFly
- 1 day ago - RBC upgrades Telix to Outperform on ITM deal benefits - TheFly
- 2 days ago - Telix Beefs Up Radioisotopes Supply With $2.35 Billion Deal; Shares Crash - Investor's Business Daily
- 2 days ago - Telix Pharmaceuticals Limited to Merge with ITM Isotope Technologies Munich SE Transcript - GuruFocus
- 2 days ago - Telix To Merge With ITM In Deal Valued At Up To $2.35 Billion - Nasdaq
- 2 days ago - Telix Pharma To Acquire ITM In Deal Worth Up To $2.35 Bln - Nasdaq